Blood group significantly influences von Willebrand factor increase and half-life after desmopressin in von Willebrand disease Vicenza

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 9, 2010, Pages 2078-2080

  Castaman, G ^a   Tosetto, A ^a   Eikenboom, J C ^b   Rodeghiero, F ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; EMOSINT; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AREA UNDER THE CURVE; BLOOD GROUP ABO SYSTEM; BLOOD GROUP SYSTEM; CLINICAL ARTICLE; DRUG HALF LIFE; FEMALE; GENE MUTATION; HUMAN; LETTER; MALE; PRIORITY JOURNAL; VON WILLEBRAND DISEASE;

ABO BLOOD-GROUP SYSTEM; ADULT; ANIMALS; AREA UNDER CURVE; DEAMINO ARGININE VASOPRESSIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; RECOMBINANT PROTEINS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 77956457893     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03957.x     Document Type: Letter

References (13)

1. Casonato A, Pontara E, Sartorello F, Cattini Mg, Sartori MT, Padrini R, Girolami A. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 2002, 99:180-4.
2. Gézsi A, Budde U, Deák I, Nagy E, Mohl A, Schlammadinger Á Boda Z, Masszi T, Sadler JE, Bodó I. Accelerated clearance alone explains ultralarge multimers in VWD Vicenza. J Thromb Haemost http://dx.doi.org/10.1111/j.1538-7836.2010.03753.x, DOI:
3. Lenting PJ, Westein E, Terraube V, Ribba A-S, Huizinga EJ, Meyer D, de Groot PG, Denis CV. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem 2004, 279:12102-9.
4. Castaman G, Tosetto A, Rodeghiero F. Reduced von Willebrand factor survival in von Willebrand disease: pathopysiologic and clinical relevance. J Thomb Haemost 2009, 7(Suppl. 1):71-4.
5. Schooten CJ, Tjernberg P, Westein E, Terraube V, Castaman G, van Mourik JA, Hollestelle MJ, Vos HL, Bertina RM, van den Berg HM, Eikenboom JCJ, Lenting PJ, Denis CV. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost 2005, 3:2228-37.
6. van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, van Genderen PJ, Fijnheer R. von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999, 94:179-85.
7. Haberichter SL, Balistreri M, Christopherson P, Morateck P, Gavazova S, Bellissimo DB, Manco-Johnson MJ, Gill JC, Montgomery RR. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006, 108:3344-51.
8. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontata E, Bertomoro A, Dandone V, Pagnan A, Casonato A. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008, 111:3540-5.
9. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987, 69:1691-5.
10. Castaman G, Eikenboom JC. ABO blood group also influences the von Willebrand factor (VWF) antigen level in heterozygous carriers of VWF null alleles, type 2N mutation Arg854Gln, and the missense mutation Cys2362Phe. Blood 2002, 100:1927-8.
11. Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008, 111:3531-9.
12. Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008, 111:4979-85.
13. Lenting PJ, van Schooten CJM, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007, 5:1353-60.